J. Li, M. Wang, M. Won, and E. G. Shaw, Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma, Int J Radiat Oncol Biol Phys, vol.81, pp.623-630, 2011.

R. Stupp, W. P. Mason, . Van-den-bent, and . Mj, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, N. Engl. J. Med, vol.352, pp.987-996, 2005.

M. Weller, M. Van-den-bent, and K. Hopkins, EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, Lancet Oncol, vol.15, pp.395-403, 2014.

R. K. Jain, E. Di-tomaso, and D. G. Duda, Angiogenesis in brain tumours, Nat. Rev. Neurosci, vol.8, pp.610-622, 2007.

J. J. Vredenburgh, A. Desjardins, and J. E. Herndon, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, vol.13, pp.1253-1262, 2007.

O. L. Chinot, W. Wick, and W. Mason, Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma, N. Engl. J. Med, vol.370, pp.709-722, 2014.

M. R. Gilbert, J. J. Dignam, and T. S. Armstrong, A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, N. Engl. J. Med, vol.370, pp.699-708, 2014.

B. Chauffert, L. Feuvret, and F. Bonnetain, Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF ?, Ann Oncol, vol.25, pp.1442-1449, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01626345

N. M. Bleehen and S. P. Stenning, A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party, Br J Cancer, vol.64, pp.769-74, 1991.

M. Niyazi, M. Brada, and A. J. Chalmers, ESTRO-ACROP guideline "target delineation of glioblastomas, Radiother. Oncol, vol.118, pp.35-42, 2016.

A. Assouline, H. Huet-de-froberville, and E. Calitchi, Arcthérapie volumétrique modulée du glioblastome près d'organes à risque. Comparaison dosimétrique avec la radiothérapie conformationnelle tridimensionnelle

. Cancer/radiothérapie, , vol.18, p.596, 2014.

P. Y. Wen, D. R. Macdonald, and D. A. Reardon, Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, J. Clin. Oncol, vol.28, pp.1963-1972, 2010.

K. B. Peters, E. Lou, A. Desjardins, D. A. Reardon, E. S. Lipp et al., Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma, Oncologist, vol.20, pp.727-735, 2015.

M. D. Walker, S. B. Green, D. P. Byar, and A. E. Jr, Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery, N Engl J Med, vol.303, pp.1323-1329, 1980.